Friday, September 28, 2007

BLOGSCAN - More Detailed Allegations About Intimidating an Avandia Whistle-Blower

On PharmaLot, this post adds some detail to previous allegations (which we most recently discussed here), that top executives, now including the top-most executive at GlaxoSmithKline tried to silence an academic physician who had doubts about the safety of rosiglitazone (Avandia). This is another reminder of the lack of transparency of the pseudo-market in pharmaceuticals. As we have said before, of course, intimidating people who blow the whistle about drug safety concerns is bad not only for the whistle-blowers, but for patients and doctors whose decisions about which treatments to give ought to be based on critical review of the best possible clinical evidence, not evidence that is filtered by secrecy and intimidation to only reflect vested interests of the makers of the treatments.


Anonymous said...

You may also want to check out a link on PharmaGossip. It's rather startling that a corporate "intimidator" is "rewarded" with a high-profile, cushy job doing humanitarian work for the Gates Foundation and also awarded knighthood. With such deep humanitarian concerns, perhaps Mr. Yamada can soon expect an honorary sainthood?

Anonymous said...

You could also check out the WSJ health blog regarding BMS being fined again for marketing issues. We seem to never run out of references for pharmas drive for profits and the willingness of people to participate for personal gain.

Steve Lucas

Extenze Side Effects said...

This is another reminder of the lack of transparency of the pseudo market in pharmaceuticals.